Search

Your search keyword '"Mitjà, Oriol"' showing total 262 results
Start Over Author "Mitjà, Oriol" Language english
262 results on '"Mitjà, Oriol"'

1. Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Author

Millat-Martinez, Pere, Gharbharan, Arvind, Alemany, Andrea, Rokx, Casper, Geurtsvankessel, Corine, Papageorgiou, Grigorios, van Geloven, Nan, Jordans, Carlijn, Groeneveld, Geert, Swaneveld, Francis, van der Schoot, Ellen, Corbacho-Monné, Marc, Ouchi, Dan, Piccolo Ferreira, Francini, Malchair, Pierre, Videla, Sebastian, García García, Vanesa, Ruiz-Comellas, Anna, Ramírez-Morros, Anna, Rodriguez Codina, Joana, Amado Simon, Rosa, Grifols, Joan-Ramon, Blanco, Julian, Blanco, Ignacio, Ara, Jordi, Bassat, Quique, Clotet, Bonaventura, Baro, Bàrbara, Troxel, Andrea, Zwaginga, Jaap Jan, Mitjà, Oriol, and Rijnders, Bart J. A.

Published
2024
Full Text
View/download PDF

2. Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study

Author

Alarcón Soto, Yovaninna, Alemany, Andrea, Bailón, Lucía, Benet, Susana, Mitjà, Oriol, Mothe, Beatriz, Paredes, Roger, Sabato, Sofía, Suñer, Clara, Torrano, Pamela, Ubals, Maria, Boreika, Rytis, Brander, Christian, Carabelli, Julieta, Carrillo, Jorge, Gallemí, Marçal, Izquierdo-Useros, Nuria, Molina-Molina, Elisa, Moraes-Cardoso, Igor, Muñoz-Basagoiti, Jordana, Olvera, Alex, Perez-Zsolt, Daniel, Raïch-Regué, Dàlia, Coll, Pep, Fernández, Javier, Mendoza, Adrià, Pérez, Félix, Reguant, Joan, Rivero, Angel, Arando, Maider, Descalzo, Vicente, Néstor Garcia, Jorge, Monforte, Arnau, Álvarez, Patricia, Guedj, Jeremie, Marc, Aurélien, Marks, Michael, Alarcón-Soto, Yovaninna, Grifoni, Alba, Sette, Alessandro, and Moltó, José

Published
2024
Full Text
View/download PDF

4. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial

Author

Ubals, Maria, Nadal-Baron, Patricia, Arando, Maider, Rivero, Ángel, Mendoza, Adrià, Descalzo Jorro, Vicent, Ouchi, Dan, Pérez-Mañá, Clara, Álvarez, Marlene, Alemany, Andrea, Hoyos-Mallecot, Yannick, Nunley, Ethan, Lieberman, Nicole A P, Greninger, Alexander L, Galván-Casas, Cristina, Suñer, Clara, G-Beiras, Camila, Paredes, Roger, Rodríguez-Gascón, Alicia, Canut, Andrés, García-Patos, Vicente, Farré, Magí, Marks, Michael, Giacani, Lorenzo, Vall-Mayans, Martí, and Mitjà, Oriol

Published
2024
Full Text
View/download PDF

6. Mpox in people with past infection or a complete vaccination course: a global case series

Author

Creticos, Catherine, Gibbons, Patrick, Maakaroun-Vermesse, Zoha, Faussat, Cathie, Handala, Lynda, Zeggagh, Jeremy, Alemany, Andrea, Galvan, Cristina, Castagna, Antonella, Raccagni, Angelo Roberto, Cruz-Flores, Raul Adrián, Fernandez Pardal, Patricia, Marchetta, Lucila, Hazra, Aniruddha, Zucker, Jason, Bell, Elizabeth, Flores, John, Gordon, Leanna, Mitjà, Oriol, Suñer, Clara, Lemaignen, Adrien, Jamard, Simon, Nozza, Silvia, Nori, Achyuta V, Pérez-Barragán, Edgar, Rodríguez-Aldama, Juan Carlos, Blanco, Jose Louis, Delaugerre, Constance, Turner, Dan, Fuertes, Irene, Leiro, Viviana, Walmsley, Sharon L, and Orkin, Chloe M

Published
2024
Full Text
View/download PDF

8. Repurposing an integrated national influenza platform for genomic surveillance of SARS-CoV-2 in Ghana: a molecular epidemiological analysis

Author

Asante, Ivy Asantewaa, Hsu, Sharon Nienyun, Boatemaa, Linda, Kwasah, Lorreta, Adusei-Poku, Mildred, Odoom, John Kofi, Awuku-Larbi, Yaw, Foulkes, Benjamin H, Oliver-Commey, Joseph, Asiedu, Ernest Konadu, Parker, Matthew D, Mitja, Oriol, Eggo, Rosalind M, de Oliveira-Martins, Leonardo, Asiedu-Bekoe, Franklin, Laryea, Dennis Odai, Kuma-Aboagye, Patrick, Marks, Michael, de Silva, Thushan I, and Ampofo, William Kwabena

Published
2023
Full Text
View/download PDF

9. Mpox in people with advanced HIV infection: a global case series

Author

Leiro, Viviana, Marchetta, Lucila, Fernandez Pardal, Patricia, Figueroa, María Inés, Cahn, Pedro, Grabmeier-Pfistershammer, Katharina, Libois, Agnes, Liesenborghs, Laurens, Grinsztejn, Beatriz, Schechter, Mauro, dos Santos de Lemos, Alberto, Furtado Costa, Alvaro, Queiroz Rocha, Simone, Valdez Madruga, José, S. Tan, Darrell H., Mishra, Sharmistha, Shah, Shreya, Jorquera, Camila, Castillo, Alberto, Carrión, Mauricio, Cevallos, Nelson, Palich, Romain, Pourcher, Valerie, Rubenstein, Emma, Migaud, Pascal, Boesecke, Christoph, Hoffmann, Christian, Protopapas, Konstantinos, Nozza, Silvia, Cattelan, Anna Maria, Mussini, Cristina, d'Arminio Monforte, Antonella, Cruz Flores, Raúl Adrian, Pérez Barragán, Edgar, Rodríguez Guzmán, Alma Leticia, Ogoina, Dimie, Chika-Igwenyi, Nneka Marian, Chizaram, Onyeaghala, Valverde López, Jenny, García Tello, Angelica, Ubals, Maria, Vall, Martí, Mendoza, Adrià, Suñer, Clara, Clotet, Bonaventura, Bechini, Jordi, Lepe, Jose A, Navarro-Amuedo, M. Dolores, Bernadino, Jose Ignacio, Català, Alba, Tarín Vicente, Eloy José, González Rodríguez, Borja, Rodriguez-Mercader, Sergi, Sánchez-Martinez, Francisca, Cañas-Ruano, Esperanza, Parra-Navarro, Laura, Filén, Finn, Tallón de Lara, Carmen, Braun, Dominique, Piezzi, Vanja, Burkhard, Michael, Kovari, Helen, Mönch, Anja, Dunning, Jake, Simoes, Pedro, Nori, Achyuta, Keegan, Sarah, Thornhill, John P, Apea, Vanessa, Noori, Teymur, Jones, Joyce L., Judson, Seth, Gilliams, Elizabeth A., Hamill, Matthew M., Keruly, Jeanne, Henao Martínez, Andrés F., Lin, Aung, So, Jessica, Davar, Kusha, Villareal, Diana, Tapia Paredes, Miguel, Mitjà, Oriol, Alemany, Andrea, Marks, Michael, Lezama Mora, Jezer I, Rodríguez-Aldama, Juan Carlos, Torres Silva, Mayara Secco, Corral Herrera, Ever Arturo, Crabtree-Ramirez, Brenda, Blanco, José Luis, Girometti, Nicolo, Mazzotta, Valentina, Hazra, Aniruddha, Silva, Macarena, Montenegro-Idrogo, Juan José, Gebo, Kelly, Ghosn, Jade, Peña Vázquez, María Fernanda, Matos Prado, Eduardo, Unigwe, Uche, Villar-García, Judit, Wald-Dickler, Noah, Zucker, Jason, Paredes, Roger, Calmy, Alexandra, Waters, Laura, Galvan-Casas, Cristina, Walmsley, Sharon, and Orkin, Chloe M

Published
2023
Full Text
View/download PDF

10. Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial

Author

Aguilar-Uroz, Adrià, Rosell-García-Ufano, Adrià, Escudero Planas, Adrián, Baelo, Aida, Villahoz Martín, Ainhoa, Moreno López, Alberto, Roldan Ruiz, Alberto, Santana Briongos, Alberto, Tejera Bodas, Alberto, Alonso-Vallés, Alejandro, Fletes-Pérez, Alejandro, Hueso-Mor, Alejandro, Boluda, Alex, Santamaria, Alex, Diestro, Alicia Santos, Revuelta-Álvarez, Almudena, Moreno Moreno, Álvaro, Ortega de Felipe, Ana, Chen-Ye, Ana, Blázquez Valerón, Ana, Rodríguez Pérez, Ana Belén, Tristán Morgalo, Ana Laura, Fernández-Allende, Ana Luisa, Bagán-Trejo, Andrea, Fernández Juan, Andrés, Zalve-Cano, Ángel, Mateo-Martínez, Anna, Galván, Antonio Valero, Egidos-Plaja, Antonio, Jorge, Ariadna, Fraile Torres, Arturo, Pareja Leal, Azahara Maria, Viader Castro, Bárbara, Fernandez Beato, Barbara, Naveira Menchen, Barbara, Martin Poyatos, Beatriz, García-Martínez, Beatriz, Rodrigo Testillano, Belén, Blanco Tejedor, Belen, López Pérez, Blanca, Mencía Hernanz, Blanca, González-Beiras, Camila, Batres, Carlos, Nuñez Garcia, Carmen, Merino-Rodríguez, Carmen, Rodríguez-Gilabert, Carolina, Bonilla Penedo, Celia, Casado Gomez, Christian, Gonzalez Perez, Claudia, Galindo-Tomás, Claudia, Peral Bolaños, Cristina, Blanco-Montes, Cristina, Lupu-Yakovleva, Cristina, Lopez Ruiz, Cristina, Perez Mayoral, Cristina, Fornes, Cristina, Garcia Corrochano, Cristobal, Gallardo Álvarez, Daniel, Navarro Sanz, Daniel, Sanz Barrio, David, Ramet Meseguer, Debora, Vera-Jurado, Edna Margarita, Perez Costa, Eduardo, Bustillos-Sebastian, Eilen Junet, Palomar Casado, Elena, Guerrero, Elena Dorrego, Medina Mateos, Elena, Aragón Gaspar, Elisa Rebeca, Herrero-Vila, Elisabeth, Paez Herrera, Enriqueta, Rojas Powel, Esmeralda, Robres Medialdea, Esther, Vall-Ribalta, Esther, Lopez Perez, Eva, Mihaela Fer, Felicia, Vazquez Ángeles, Fernanda, Tirado Bejarano, Fernando, Prats-Domenech, Ferran, Borràs Martí, Ferran, Ardila-Mejia, Gabriela, Costes, Gèlia, Gómez Arquero, Gema, Flores Mateo, Gemma, Pintos-Morell, Guillem, Mira-Centelles, Helena, Astola Requena, Ignacio, Ortega Martin, Ignacio, Leivas-Gutierrez, Iker, Escribano Valenciano, Irene, Muñoz Gomez, Irene, Ortega, Irina, Montserrat-Lloan, Isabel, Gamboa, Itziar, Rodríguez de Torres de Paul, Jacobo, Cahís, Jordi, Muñoz-Martinez, Jordi, Bermejo, Jorge Iglesias, Cejas López, Joselvis Virginia, Canudas, Josep, García Lucas, Juan Antonio, Martínez-Pino, Juan Carlos, Torres Martínez, Juana, Pujol-Corney, Judit, González Jiménez, Judith, Gurí, Júlia, Labella Martín, Julio, Garcia-Cano, Laia, Perez Plata, Lara Sonsoles, Muñoz Álvaro, Laura, Rodríguez Andrés, Laura, Vega Ruiz, Laura, Cuevas Valiente, Laura, Díaz Rodríguez, Laura, Puigros, Laura, Cristina Piciorang, Lavinia, Escudero, Leticia, Figueroa Caballero, Liliana, Ferrerfàbrega-Costals, Lluna, Costafreda-Hernández, Lucía, De-Paúl, Lucía, González Fernández-Medina, Luis, Moliner Prada, M<ce:sup loc='post">a</ce:sup> Carmen, Berriochoa Martínez de Pisón, M<ce:sup loc='post">a</ce:sup> Cristina, Blanco Blasco, Maria, Gil Jorge, Maria, Cortijo Caballero, María, Ubals, Maria, Gordillo, Maria, Guilloto López, Maria Alicia, Moreno Calvo, Maria Concepción, Gil García, María del Rosario, Dueñas Román, María Inmaculada, Gonzalez Sanchez, Maria Josefa, Nicolás Campoy, María Luisa, González Velayos, Maria Luz, Zori, Mario Mejías, Maqueda, Mario Oliva, Caño de la Cruz, Mario, Palau-Morral, Mariona, Martín-Muñoz, Marta, Cereceda Meca, Marta, Díaz Urbina, Marta, VerónicaPlazas, Martha, Vall-Mayans, Martí, Blasco, Martí, Jane Chu-Sifuentes, Mary, García de Villasladad Peñaranda, Miguel, Hernanz Sotoca, Miguel, Iglesias Gonzalez, Miguel, Labrador-Galván, Miguel Ángel, Rodrigo de Vivar Azcarate, Miguel, Gil-Fibla, Miquel, Formentí-Pallarés, Miquel, Esteve-Tugues, Mireia, Juanes Perez, Miriam, López Rubio, Miriam, Recuero Renales, Mirian, Hijós-Rullo, Mònica, Lleonart-Abadia, Montserrat, Finelli, Nadia, Rojas-Bertier, Naiara, Reyes-Calderón, Nataly, Casado Larrañaga, Nerea, Zurita Castrosin, Nerea Nuria, Álvarez-Nieto, Noélia, Leiva-Mora, Nuria, Tomillo-Martín, Olga, Belghazi, Omar, Buscà, Oriol, Mendoza Cediel, Pablo, Macedo, Pablo, Rodríguez Barroso, Patricia, Ruiz Álvarez, Patricia, López, Patricia Morales, Vara de Rey, Patricia Jimenez, Ginés, Paz Lozano, Bris Rodriguez, Pilar, Martínez-Alamillo, Pilar, Salmerón Martínez, Rafa, Botello Ariza, Raquel, Vaquero Mena, Raquel, González-Alonso, Raquel, Kaczmarczyk, Raul, Barnadas Vintró, Rita, Hontecillas Martínez, Rodrigo, Ribot-Rodríguez, Rosa, Escobar-Sánchez, Rosa, Montes Trinidad, Rosario Paloma, Martínez Quintana, Rubén, Arnay Arrogante, Ruben, Berjon Sanchez, Ruben, Picazo Navarro, Ruben, Bastos, Rubén, Martín Molinero, Samuel, Israel-Benchaya, Samuel Dan, Muñoz-Burguillo, Sandra, Rodríguez-Salvador, Sandra, Avila, Sara, Corral Gayubas, Sara, Nuñez Sánchez, Sergio, Torres Weber, Sofía, Encabo Lopez, Susana, Torices Rasines, Teresa, Sallas, Valentí, Curto-Vicente, Verónica, Gómez Hijosa, Verónica, Daimiel-Pedrote, Verónica, Gozalo, Verónica, Barrios López, Vicente, Castillo Montoya, Virginia Ivette, Espinoza Pérez, Yuri, CristinaBerriochoa Martínez de Pisón, María, Muñoz Castillo, David, Donato, Carlos, García García, Isabel, Alemany, Andrea, Millat-Martinez, Pere, Corbacho-Monné, Marc, Suñer, Clara, Galvan-Casas, Cristina, Carrera, Caty, Ouchi, Dan, Prat, Núria, Ara, Jordi, Nadal, Nuria, Riel, Ricard, Funollet, Blanca, Ojeda-Ciurana, Carmen, Balague, Lluis Esteve, Salvador-González, Betlem, Arcarons, Anna Forcada, Vidal-Alaball, Josep, Del Cura-González, María Isabel, Barrientos, Ricardo Rodríguez, Ramos-Blanes, Rafel, Bou, Alberto Alum, Mondou, Elsa, Torres, Mireia, Campins, Neus, Sanz, Ana, Tang, Yonggiang, Rodriguez-Arias, Miquel Àngel, Bassat, Quique, Clotet, Bonaventura, and Mitjà, Oriol

Published
2023
Full Text
View/download PDF

11. Monkeypox

Author

Mitjà, Oriol, Ogoina, Dimie, Titanji, Boghuma K, Galvan, Cristina, Muyembe, Jean-Jacques, Marks, Michael, and Orkin, Chloe M

Published
2023
Full Text
View/download PDF

12. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study

Author

Tarín-Vicente, Eloy José, Alemany, Andrea, Agud-Dios, Manuel, Ubals, Maria, Suñer, Clara, Antón, Andrés, Arando, Maider, Arroyo-Andrés, Jorge, Calderón-Lozano, Lorena, Casañ, Cristina, Cabrera, José Miguel, Coll, Pep, Descalzo, Vicente, Folgueira, María Dolores, García-Pérez, Jorge N, Gil-Cruz, Elena, González-Rodríguez, Borja, Gutiérrez-Collar, Christian, Hernández-Rodríguez, Águeda, López-Roa, Paula, de los Ángeles Meléndez, María, Montero-Menárguez, Julia, Muñoz-Gallego, Irene, Palencia-Pérez, Sara Isabel, Paredes, Roger, Pérez-Rivilla, Alfredo, Piñana, María, Prat, Nuria, Ramirez, Aída, Rivero, Ángel, Rubio-Muñiz, Carmen Alejandra, Vall, Martí, Acosta-Velásquez, Kevin Stephen, Wang, An, Galván-Casas, Cristina, Marks, Michael, Ortiz-Romero, Pablo L, and Mitjà, Oriol

Published
2022
Full Text
View/download PDF

14. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Author

Millat-Martinez, Pere, Gharbharan, Arvind, Alemany, Andrea, Rokx, Casper, Geurtsvankessel, Corine, Papageorgiou, Grigorios, van Geloven, Nan, Jordans, Carlijn, Groeneveld, Geert, Swaneveld, Francis, van der Schoot, Ellen, Corbacho-Monné, Marc, Ouchi, Dan, Piccolo Ferreira, Francini, Malchair, Pierre, Videla, Sebastian, García García, Vanesa, Ruiz-Comellas, Anna, Ramírez-Morros, Anna, Rodriguez Codina, Joana, Amado Simon, Rosa, Grifols, Joan-Ramon, Blanco, Julian, Blanco, Ignacio, Ara, Jordi, Bassat, Quique, Clotet, Bonaventura, Baro, Bàrbara, Troxel, Andrea, Zwaginga, Jaap Jan, Mitjà, Oriol, and Rijnders, Bart J. A.

Published
2022
Full Text
View/download PDF

15. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial

Author

Ferrer, Susana, Gallardo, Mireia, Ubals, Maria, González-Beiras, Camila, Vall-Mayans, Martí, Suñer, Clara, Laporte-Villar, Clàudia, Nieto, Aroa, Comas-Leon, Xavier, Jiménez, Zahida, Ramírez-Viaplana, Ferran, Delgado-Capel, Maria, Díez Sánchez, Beatriz, Pons Barber, Maria, Gonzalez Ruiz, Cristian, Navarrete Gonzalez, Laura, González García, David, Vivero Larraza, Ainhoa, Carceles Peiró, Victor, Roquer López, Clàudia, Robert, Neus, Palet, Carles, Gudiol, Carlota, Casares Gonzalez, Pablo, Arcos Vila, Gemma, Flores Aguilera, Begoña, Rodríguez-Sevilla, Graciela, Dastis Arias, Macarena, Roca Font, Judit, Carrasco Matos, Katherine M., Saüch Valmaña, Glòria, Vidal Obradors, Carla, Tarres García, Silvia, Curriu Sabatès, Margarida, Nieto Rodríguez, Raquel, Línio, Rosa, Fornos, Míriam, Casamitjana, Natàlia, Alonso, Eva, Martínez, Núria, Maglio, Laura Analía, Comellas Fernandez, Laura, Garcia, Nadia, Hernández, Luis, González, Maria Isabel, Bravo, Anna, García, Yolanda, Sauleda Oliveras, Silvia, Vertiz, Tatiana, Benavent, Sergio, Bianco, Andrea Sofia, Verdaguer, Joaquim, Briones Zambrano, Ney Nicanor, Viozquez Meya, Maria, Hernández, Águeda, Casaña Lopez, Cristina, Bordoy, Antoni E., González Soler, Victoria, Giménez, Montserrat, París, Alexa, Marfil, Silvia, Trinité, Benjamin, Grau, Eulàlia, Alemany, Andrea, Millat-Martinez, Pere, Corbacho-Monné, Marc, Malchair, Pierre, Ouchi, Dan, Ruiz-Comellas, Anna, Ramírez-Morros, Anna, Rodríguez Codina, Joana, Amado Simon, Rosa, Videla, Sebastian, Costes, Gèlia, Capdevila-Jáuregui, Mar, Torrano-Soler, Pamela, San José, Alba, Bonet Papell, Glòria, Puig, Jordi, Otero, Aurema, Ruibal Suarez, Jose Carlos, Zarauza Pellejero, Alvaro, Llopis Roca, Ferran, Rodriguez Cortez, Orlando, Garcia Garcia, Vanesa, Vidal-Alaball, Josep, Millan, Anna, Contreras, Enric, Grifols, Joan-Ramon, Ancochea, Àgueda, Galvan-Femenia, Ivan, Piccolo Ferreira, Francini, Bonet, Mireia, Cantoni, Jordi, Prat, Núria, Ara, Jordi, Forcada Arcarons, Anna, Farré, Magí, Pradenas, Edwards, Blanco, Julià, Àngel Rodriguez-Arias, Miquel, Fernández Rivas, Gema, Marks, Michael, Bassat, Quique, Blanco, Ignacio, Baro, Bàrbara, Clotet, Bonaventura, and Mitjà, Oriol

Published
2022
Full Text
View/download PDF

17. Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series

Author

Thornhill, John P, Palich, Romain, Ghosn, Jade, Walmsley, Sharon, Moschese, Davide, Cortes, Claudia P, Galliez, Rafael Mello, Garlin, Amy B, Nozza, Silvia, Mitja, Oriol, Radix, Asa E, Blanco, Jose Luis, Crabtree-Ramirez, Brenda, Thompson, Melanie, Wiese, Lothar, Schulbin, Hubert, Levcovich, Ariela, Falcone, Marco, Lucchini, Anna, Sendagorta, Elena, Treutiger, Carl-Johan, Byrne, Ruth, Coyne, Katherine, Meyerowitz, Eric A, Grahn, Anna M, Hansen, Ann-Brit Eg, Pourcher, Valerie, DellaPiazza, Michelle, Lee, Rachel, Stoeckle, Marcel, Hazra, Aniruddha, Apea, Vanessa, Rubenstein, Emma, Jones, Joyce, Wilkin, Aimee, Ganesan, Anuradha, Henao-Martínez, Andrés F, Chow, Eric J, Titanji, Boghuma K, Zucker, Jason E, Ogoina, Dimie, and Orkin, Chloe M

Published
2022
Full Text
View/download PDF

18. Sequence typing of Haemophilus ducreyi isolated from patients in the Namatanai region of Papua New Guinea: Infections by Class I and Class II strain types differ in ulcer duration and resurgence of infection after azithromycin treatment.

Author

Medappa, Monica, Pospíšilová, Petra, John, Lucy N., González-Beiras, Camila, Vall-Mayans, Marti, Mitjà, Oriol, and Šmajs, David

Subjects
GENETIC variation, HAEMOPHILUS, DRUG administration, ULCERS, TREPONEMA pallidum, AZITHROMYCIN
Abstract

Haemophilus ducreyi (HD) is an important cause of cutaneous ulcers in several endemic regions, including the Western Pacific Region, especially among children. An HD sequence typing on swab samples taken from 1,081 ulcers in the Namatanai district of Papua New Guinea, during the pilot study for treatment of yaws, has been performed using the Grant typing system. Of the 363 samples that tested positive for the 16S rDNA of HD, the dsrA sequences of 270 samples were determined. Altogether they revealed 8 HD strain types circulating in Namatanai, including seven strain types of Class I (I.3, I.4, I.5, I.9, I.10, I.11, I.12) and one strain of Class II (II.3); four Class I types (I.9, I.10, I.11, I.12) were novel. The southern region of Namatanai (Matalai Rural) was identified as the region with the lowest genotype diversity and with most infections caused by HD Class II. The middle and northern subdistricts were affected mainly by HD Class I. Analysis of patient characteristics revealed that Class II HD infections were more often represented by longer-lasting ulcers than Class I HD infections. An increase in the prevalence of the I.10 strain was found after azithromycin administration compared to the untreated population at baseline likely reflecting higher infectivity of HD Class I, and more specifically strain type I.10. Author summary: Haemophilus ducreyi (HD) is one of the main causative agents of cutaneous ulcers in children across substantial parts of Africa and the Pacific. A yaws eradication study conducted in the Namatanai district of Papua New Guinea revealed that nearly one-third of all patients were infected with HD. Single locus sequence typing (SLST) of the HD dsrA locus revealed presence of multiple HD strains circulating in the human population of Namatanai region. In contrast to Treponema pallidum subsp. pertenue, the pathogen responsible for yaws, the prevalence of HD strains did not significantly decrease following mass drug administration. In addition, HD strains from patients in Namatanai region revealed a higher genetic diversity compared to the yaws agent present in the same area and the HD strain composition changed following antibiotic treatment. Infections caused by at least some different HD strain types appear to differ in reported ulcer duration and also in resurgence of infection after antibiotic treatment. Therefore, important pathophysiological differences among HD strain types were predicted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. A retrospective cohort study of risk factors for mortality among nursing homes exposed to COVID-19 in Spain

Author

Suñer, Clara, Ouchi, Dan, Mas, Miquel Àngel, Lopez Alarcon, Rosa, Massot Mesquida, Mireia, Prat, Núria, Bonet-Simó, Josep Maria, Expósito Izquierdo, Marta, Garcia Sánchez, Irene, Rodoreda Noguerola, Sara, Teixidó Colet, Montserrat, Verdaguer Puigvendrelló, Joaquim, Henríquez, Norma, Miralles, Ramón, Negredo, Eugènia, Noguera-Julian, Marc, Marks, Michael, Estrada, Oriol, Ara, Jordi, and Mitjà, Oriol

Published
2021
Full Text
View/download PDF

22. Coverage, determinants of use and repurposing of long-lasting insecticidal nets two years after a mass distribution in Lihir Islands, Papua New Guinea: a cross-sectional study

Author

Millat-Martínez, Pere, Gabong, Rebecca, Balanza, Núria, Luana, Sakaia, Sanz, Sergi, Raulo, Silvia, Elizah, Arthur, Wali, Chilaka, Paivu, Benjamin, Dalmas, Julian, Tabie, Samson, Karl, Stephan, Laman, Moses, Pomat, William, Mitjà, Oriol, Baro, Bàrbara, and Bassat, Quique

Published
2021
Full Text
View/download PDF

23. Low genetic diversity of Treponema pallidum ssp. pertenue (TPE) isolated from patients' ulcers in Namatanai District of Papua New Guinea: Local human population is infected by three TPE genotypes.

Author

Medappa, Monica, Pospíšilová, Petra, Madruga, Maria Paula M., John, Lucy N., Beiras, Camila G., Grillová, Linda, Oppelt, Jan, Banerjee, Arka, Vall-Mayans, Marti, Mitjà, Oriol, and Šmajs, David

Subjects
TREPONEMA pallidum, GENETIC variation, GENOTYPES, ULCERS, SERODIAGNOSIS, ENDEMIC diseases
Abstract

Yaws is an endemic disease caused by Treponema pallidum subsp. pertenue (TPE) that primarily affects children in rural regions of the tropics. The endemic character of yaws infections and the expected exclusive reservoir of TPE in humans opened a new opportunity to start a yaws eradication campaign. We have developed a multi-locus sequence typing (MLST) scheme for TPE isolates combining the previously published (TP0548, TP0488) and new (TP0858) chromosomal loci, and we compared this typing scheme to the two previously published MLST schemes. We applied this scheme to TPE-containing clinical isolates obtained during a mass drug administration study performed in the Namatanai District of Papua New Guinea between June 2018 and December 2019. Of 1081 samples collected, 302 (28.5%) tested positive for TPE DNA, from which 255 (84.4%) were fully typed. The TPE PCR-positivity in swab samples was higher in younger patients, patients with single ulcers, first ulcer episodes, and with ulcer duration less than six months. Non-treponemal serological test positivity correlated better with PCR positivity compared to treponema-specific serological tests. The MLST revealed a low level of genetic diversity among infecting TPE isolates, represented by just three distinct genotypes (JE11, SE22, and TE13). Two previously used typing schemes revealed similar typing resolutions. Two new alleles (one in TP0858 and one in TP0136) were shown to arise by intragenomic recombination/deletion events. Compared to samples genotyped as JE11, the minor genotypes (TE13 and SE22) were more frequently detected in samples from patients with two or more ulcers and patients with higher values of specific TP serological tests. Moreover, the A2058G mutation in the 23S rRNA genes of three JE11 isolates was found, resulting in azithromycin resistance. Author summary: Yaws is an endemic disease that currently affects marginalized populations in thirteen countries. While the first yaws eradication effort in the 1950s resulted in a dramatic reduction of yaws cases, a resurgence of yaws has been observed in recent years. New treatment options including a single oral dose of azithromycin as well as new treatment regimens open a new opportunity to restart yaws eradication. The bacterium causing yaws, Treponema pallidum ssp. pertenue (TPE), has been characterized in this study with a newly developed multilocus sequence typing (MLST) scheme for TPE isolates collected during the Yaws 3 Trial held in the Namatanai District of Papua New Guinea. Altogether, 3 distinct TPE genotypes (JE11, SE22, and TE13) have been found as well as two new alleles of analysed loci that were shown to arise by intragenomic recombination/deletion events. Our typing method and meta-analysis may aid the ongoing yaws eradication campaign by distinguishing of infecting TPE strains to help control yaws transmission, monitoring antibiotic resistance emergence and patient reinfection in high-risk areas through targeted interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization

Author

Levine, Adam C, Fukuta, Yuriko, Huaman, Moises A, Ou, Jiangda, Meisenberg, Barry R, Patel, Bela, Paxton, James H, Hanley, Daniel F, Rijnders, Bart Ja, Gharbharan, Arvind, Rokx, Casper, Zwaginga, Jaap Jan, Alemany, Andrea, Mitjà, Oriol, Ouchi, Dan, Millat-Martinez, Pere, Durkalski-Mauldin, Valerie, Korley, Frederick K, Dumont, Larry J, Callaway, Clifton W, Libster, Romina, Marc, Gonzalo Perez, Wappner, Diego, Esteban, Ignacio, Polack, Fernando, Sullivan, David J, Internal Medicine, Surgery, and Medical Microbiology & Infectious Diseases

Subjects
Microbiology (medical), Infectious Diseases
Abstract

Background Outpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma (CCP) is promising, clinical trials among outpatients have shown mixed results. Methods We conducted an individual participant data meta-analysis from outpatient trials to assess the overall risk reduction for all-cause hospitalizations by day 28 in transfused participants. Relevant trials were identified by searching Medline, Embase, medRxiv, World Health Organization COVID-19 Research Database, Cochrane Library, and Web of Science from January 2020 to September 2022. Results Five included studies from 4 countries enrolled and transfused 2620 adult patients. Comorbidities were present in 1795 (69%). The virus neutralizing antibody dilutional titer levels ranged from 8 to 14 580 in diverse assays. One hundred sixty of 1315 (12.2%) control patients were hospitalized, versus 111 of 1305 (8.5%) CCP-treated patients, yielding a 3.7% (95% confidence interval [CI], 1.3%–6.0%; P = .001) absolute risk reduction and 30.1% relative risk reduction for all-cause hospitalization. The hospitalization reduction was greatest in those with both early transfusion and high titer with a 7.6% absolute risk reduction (95% CI, 4.0%–11.1%; P = .0001) accompanied by at 51.4% relative risk reduction. No significant reduction in hospitalization was seen with treatment >5 days after symptom onset or in those receiving CCP with antibody titers below the median titer. Conclusions Among outpatients with COVID-19, treatment with CCP reduced the rate of all-cause hospitalization and may be most effective when given within 5 days of symptom onset and when antibody titer is higher.

Published
2023

27. Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea

Author

Marks, Michael, Mitjà, Oriol, Bottomley, Christian, Kwakye, Cynthia, Hounei, Wendy, Bauri, Mathias, Adwere, Paul, Abdulai, Abdul A, Dua, Fredrick, Boateng, Laud, Wangi, James, Ohene, Sayy-Ann, Wangnapi, Regina, Simpson, Shirley V, Miag, Helen, Addo, Kennedy K, Basing, Laud A, Danavall, Damien, Chi, Kai H, Pillay, Allan, Ballard, Ronald, Solomon, Anthony W, Chen, Cheng Y, Bieb, Sivuak V, Adu-Sarkodie, Yaw, Mabey, David CW, Asiedu, Kingsley, Agana, Nsire, Ampadu, Edwin, Amponsah-Achiano, Kwame, Bediako, Asare, Biredu, Michael, Faried, Kyei, Iddrisu, Ahmed, Kotey, Nana K, Yeboah, George NY, El-Duah, Philip, Phillips, Richard, Binka, Fred, Nyonator, Frank, Zunuo, Anthony, Ackumey, Mercy A, Amanor, Ivy, Bnosu, Christian, Frischmann, Sieghard, Lammie, Patrick, Martin, Diana, Ye, Tun, Christophel, Eva, Tiendrebeogo, Alexandre, Vestergard, Lasse, Bassat, Quique, Abdad, Yazid, Dima, Henson, Kotty, Bethuel, Mamore, Kaiok, Manup, Walerius, Olowau, Benson, Agyei, Enoch O, Agyemang, David, Ako, Ebenezer P, Antwi, Prince, Darko, Jane, Darko, Ophelia O, Darko, Phylis, Duodu, Bertha, Jabasi, Daniel, Karim, Fuseini L, Koomson, Obed K, Labri, Bernard A, Nartey, John, Tamatey, Randsford, Yirenkyi, Benjamin, Arhin, Mercy, Biney, Frank, Danso, Juliana O, Dei, Martin A, Djan, Moses, Sasu, Samuel, Solomon, Brefo A, Torvinya, Victor, Amankwaah, Hagar, Baffoe, James, Keteku, Lydia, Kondobala, Kofi, Lomotey, Rita D, Nartey, Augustina A, Oppong, Paul, Quainoo, Millicent A, Abotsi, Theophilus, Agebshie, Dzighordi, Ameamu, Amos, Angwaawie, Paul, Ayibor, Rose, Mwingmendeli, Margaret, Nakodia, John, Nambagyira, Amatus, Nanga, Dominic, Tetteh, Nichola, Wanaom, Augustine, Houinei, Wendy, Ohene, Sally-Ann, Bieb, Sibauk V, and Mabey, David C W

Published
2018
Full Text
View/download PDF

29. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.

Author

Nguyen, Bach Tran, Marc, Aurélien, Suñer, Clara, Marks, Michael, Ubals, Maria, Hernández-Rodríguez, Águeda, Melendez, María Ángeles, Hruby, Dennis E., Russo, Andrew T., Mentré, France, Mitjà, Oriol, Grosenbach, Douglas W., and Guedj, Jérémie

Subjects
MONKEYPOX, BASIC reproduction number, REPRODUCTION, PEAK load, DRUG efficacy, VIRAL load
Abstract

Despite use of tecovirimat since the beginning of the 2022 outbreak, few data have been published on its antiviral effect in humans. We here predict tecovirimat efficacy using a unique set of data in nonhuman primates (NHPs) and humans. We analyzed tecovirimat antiviral activity on viral kinetics in NHP to characterize its concentration–effect relationship in vivo. Next, we used a pharmacological model developed in healthy volunteers to project its antiviral efficacy in humans. Finally, a viral dynamic model was applied to characterize mpox kinetics in skin lesions from 54 untreated patients, and we used this modeling framework to predict the impact of tecovirimat on viral clearance in skin lesions. At human-recommended doses, tecovirimat could inhibit viral replication from infected cells by more than 90% after 3 to 5 days of drug administration and achieved over 97% efficacy at drug steady state. With an estimated mpox within-host basic reproduction number, R0, equal to 5.6, tecovirimat could therefore shorten the time to viral clearance if given before viral peak. We predicted that initiating treatment at symptom onset, which on average occurred 2 days before viral peak, could reduce the time to viral clearance by about 6 days. Immediate postexposure prophylaxis could not only reduce time to clearance but also lower peak viral load by more than 1.0 log10 copies/mL and shorten the duration of positive viral culture by about 7 to 10 days. These findings support the early administration of tecovirimat against mpox infection, ideally starting from the infection day as a postexposure prophylaxis. Despite its use since the beginning of the 2022 mpox outbreak, few data have been published on the antiviral effect of tecovirimat in humans. This study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach that combines pre-clinical and clinical data. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Global epidemiology of yaws: a systematic review

Author

Mitjà, Oriol, Marks, Michael, Konan, Diby J P, Ayelo, Gilbert, Gonzalez-Beiras, Camila, Boua, Bernard, Houinei, Wendy, Kobara, Yiragnima, Tabah, Earnest N, Nsiire, Agana, Obvala, Damas, Taleo, Fasiah, Djupuri, Rita, Zaixing, Zhang, Utzinger, Jürg, Vestergaard, Lasse S, Bassat, Quique, and Asiedu, Kingsley

Published
2015
Full Text
View/download PDF

36. Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials.

Author

Levine, Adam C, Fukuta, Yuriko, Huaman, Moises A, Ou, Jiangda, Meisenberg, Barry R, Patel, Bela, Paxton, James H, Hanley, Daniel F, Rijnders, Bart J A, Gharbharan, Arvind, Rokx, Casper, Zwaginga, Jaap Jan, Alemany, Andrea, Mitjà, Oriol, Ouchi, Dan, Millat-Martinez, Pere, Durkalski-Mauldin, Valerie, Korley, Frederick K, Dumont, Larry J, and Callaway, Clifton W

Subjects
MEDICAL databases, RELATIVE medical risk, META-analysis, MEDICAL information storage & retrieval systems, CONFIDENCE intervals, IMMUNOGLOBULINS, SYSTEMATIC reviews, PREVENTIVE health services, CONVALESCENT plasma, HOSPITAL care, DESCRIPTIVE statistics, MEDLINE, COVID-19 pandemic, OUTPATIENT services in hospitals, COMORBIDITY
Abstract

Background Outpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma (CCP) is promising, clinical trials among outpatients have shown mixed results. Methods We conducted an individual participant data meta-analysis from outpatient trials to assess the overall risk reduction for all-cause hospitalizations by day 28 in transfused participants. Relevant trials were identified by searching Medline, Embase, medRxiv, World Health Organization COVID-19 Research Database, Cochrane Library, and Web of Science from January 2020 to September 2022. Results Five included studies from 4 countries enrolled and transfused 2620 adult patients. Comorbidities were present in 1795 (69%). The virus neutralizing antibody dilutional titer levels ranged from 8 to 14 580 in diverse assays. One hundred sixty of 1315 (12.2%) control patients were hospitalized, versus 111 of 1305 (8.5%) CCP-treated patients, yielding a 3.7% (95% confidence interval [CI], 1.3%–6.0%; P =.001) absolute risk reduction and 30.1% relative risk reduction for all-cause hospitalization. The hospitalization reduction was greatest in those with both early transfusion and high titer with a 7.6% absolute risk reduction (95% CI, 4.0%–11.1%; P =.0001) accompanied by at 51.4% relative risk reduction. No significant reduction in hospitalization was seen with treatment >5 days after symptom onset or in those receiving CCP with antibody titers below the median titer. Conclusions Among outpatients with COVID-19, treatment with CCP reduced the rate of all-cause hospitalization and may be most effective when given within 5 days of symptom onset and when antibody titer is higher. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis.

Author

Alshehri, Abdullah, Chhonker, Yashpal S., Bala, Veenu, Edi, Constant, Bjerum, Catherine M., Koudou, Benjamin G., John, Lucy N., Mitjà, Oriol, Marks, Michael, King, Christopher L., and Murry, Daryl J.

Subjects
FILARIASIS, DRUG administration, PHARMACOKINETICS, IVERMECTIN, POISONS
Abstract

Background: Ivermectin (IVM) is a broad–spectrum anthelmintic drug used to treat diseases caused by filarial worms, such as onchocerciasis and lymphatic filariasis (LF). IVM is part of a triple–drug therapy used by the Mass Drug Administration (MDA) as a preventive strategy to eradicate LF in sub–Saharan Africa. The drug shows high variability in drug exposure in previous pharmacokinetic studies. This study aims to build a population pharmacokinetic (PopPK) model to identify and quantify the possible sources of the variability of IVM exposure after a single–oral dose in LF–infected subjects and healthy individuals. Methodology / Principal findings: In this analysis, 724 samples were collected from treatment–naïve Wuchereria bancrofti–infected (n = 32) and uninfected (n = 24) adults living in Côte d'Ivoire who had received one dose of IVM as a part of triple–drug therapy. PopPK analysis was conducted using Phoenix NLME 8.3 software. The Monte Carlo simulation based on the final model was performed to simulate drug exposure among different dosing groups (200 μg/kg, 18 mg, and 36 mg). A two–compartment model with zero–order dose input into the absorption compartment with a lag time function followed by first–order absorption and linear elimination best described the IVM's pharmacokinetic (PK) parameters. The final model identifies that the PK parameters of IVM are not affected by LF infection. Sex was a significant covariate on the peripheral volume of distribution (Vp/F, 53% lower in men than in women). IVM drug exposure shows linear pharmacokinetic behavior among the simulated dosing groups with similar drug exposure based on sex. Conclusion/Significance: We have developed a PopPk model to describe and identify possible sources of the variability of IVM exposure. To our knowledge, this is the first PopPK study of IVM in patients with LF. Trial registration: NCT02845713; NCT03664063 Author summary: Ivermectin has been shown to be a valuable tool in mass drug administration campaigns against lymphatic filariasis. The drug shows high variability in drug exposure in previous pharmacokinetic studies. Variability in drug exposure can lead to either a higher exposure with the potential for toxic effects or a lower exposure that may result in treatment failure. Identifying and quantifying the source of high variability using non–linear mixed effects modeling is crucial for future dosing recommendations that seek to maximize therapeutic benefit while minimizing toxicity risks. In this study, the variability of IVM exposure after a single oral dose was investigated with a population pharmacokinetic model using data from Lymphatic filariasis infected subjects and healthy individuals. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Author

Rokx, Casper, Lammers, Jolanda, Buitenhuis, Lonneke, Postma, Douwe, Koster, David, Lukens, Michaèl, Scholtens, Thea, Boomgaard, Maartje van den, Kampschreur, Linda, Ubals, Maria, Prat, Núria, Díez Sánchez, Beatriz, Vértiz Guidotti, Thatiana, Pons Barber, Maria, Gonzalez Ruiz, Cristian, Navarrete Gonzalez, Laura, Ancochea, Àgueda, Ferrer, Magí, Videla, Sebas, Gudiol, Carlota, Fernández Rivas, Gema, CoV-Early Study Group, Vonderen, Marit van, Bianco, Andrea Sofia, Bravo, Anna, Otero, Aurema, Ruibal Suarez, Jose Carlos, Benavent, Sergio, Zarauza Pellejero, Alvaro, Línio, Rosa, Malchair, Pierre, Llopis Roca, Ferran, Blanco, Julian, Rodriguez Cortez, Orlando, Casares Gonzalez, Pablo, Arcos Vila, Gemma, García, Yolanda, Roca Font, Judit, Carrasco Matos, Katherine M., Saüch Valmaña, Glòria, Vidal Obradors, Carla, Koopmans, Marion, Ara, Jordi, COnV-ert Study Group, Rodríguez Codina, Joana, Tarres García, Silvia, Blanco, Ignacio, Hernández, Águeda, González Soler, Victoria, Curriu Sabatès, Margarida, Nieto Rodríguez, Raquel, Grífols, Joan Ramon, Briones Zambrano, Ney Nicanor, Millan, Anna, Capdevila Jáuregui, Mar, Fornos, Miriam, Casamitjana, Natàlia, Bordoy, Antoni E., Alonso, Eva, Zwet, Erik van, Miedema, Jelle, Martinez, Núria, Ramírez Morros, Anna, Bogers, Susanne, Maglio, Laura Analía, Amado Simon, Rosa, Comellas Fernandez, Laura, Garcia, Nadia, Ruiz Comellas, Anna, Baro, Bàrbara, Hernández, Luis, Viozquez Meya, Maria, Costes, Gèlia, Pradenas, Edwars, Forcada, Anna, Ginneken, Betty van, Harvala, Heli, Marfil, Silvia, Troxel, Andrea, Mooijaart, Simon, Trinité, Benjamin, Piccolo Ferreira, Francini, Bonet, Mireia, Cantoni, Jordi, Russcher, Henk, Marks, Michael, Zwaginga, Jaap Jan, Torrano Soler, Pamela, Mitjà, Oriol, Rijnders, Bart J. A., Droog, José de, Corbacho Monné, Marc, Scherpenisse, Cees, Hollander, Jan den, Gharbharan, Arvind, Jordans, Carlijn, Geurtsvankessel, Corine, Albersen, Arjan, Papageourgiou, Grigorios, Katsikis, Peter, Vall Mayans, Martí, Müller, Yvonne, Reusken, Chantal, San José, Alba, Ferrer, Susana, Engen, Rene van, Karisli, Ayten, Götz, Hannelore, Struik, Jelle, París, Alexa, Suñer Navarro, Clara, Clotet, Bonaventura, 1953, Reimerink, Johan, Rokx-Niemantsverdriet, Lotte, Rodriguez Arias, Miquel Angel, Jiménez, Zahida, Verstijnen, Jose, Geloven, Nan van, Groeneveld, Geert, Zwaginga, Lisa, Oud, Josine, Meier, Romy, González Beiras, Camila, Swaneveld, Francis, Ramírez Viaplana, Ferran, Schoot, Ellen van der, Vrielink, Hans, Flores Aguilera, Begoña, Vivero Larraza, Ainhoa, Watering, Leo van de, Hogema, Boris, González García, David, Wijngaarden, Peter van, Vidal Alaball, Josep, Etten, Ronald van, Gammeren, Adriaan van, Alemany, Andrea, Puig, Jordi, Maas, Nanda, Berg – Rahman, Juliette van der, Karim, Faiz, Hiddema, Siepke, Elst, Kim van, García García, Vanesa, Casañ Lopez, Cristina, Leeuwen-Segarceanu, Elena van, Nieto, Aroa, Rodríguez Sevilla, Graciela, Reitsma, Annette, Molenkamp, Karin, Soetekouw, Robert, Band, Caterina, Carceles Peiró, Victor, Gallardo, Mireia, Galvan Femenia, Ivan, Comas Leon, Xavier, Millat Martínez, Pere, Bassat Orellana, Quique, González, María Isabel, Verdaguer, Joaquim, Roquer López, Clàudia, Contreras, Enric, Giménez, Montserrat, Ouchi, Dan, Blanco Guillermo, Ignacio, Bonet Papell, Glòria, Dastis Arias, Macarena, Delgado Capel, Maria, Faculteit Medische Wetenschappen/UMCG, Internal Medicine, Medical Microbiology & Infectious Diseases, Virology, and Epidemiology

Subjects
Immunoregulació, Multidisciplinary, SARS-CoV-2, Immunization, Passive, Immunoregulation, COVID-19, General Physics and Astronomy, Bayes Theorem, General Chemistry, Middle Aged, General Biochemistry, Genetics and Molecular Biology, Treatment Outcome, Outpatients, Humans, Multicenter Studies as Topic, COVID-19 Serotherapy, Randomized Controlled Trials as Topic
Abstract

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when Trial registration: Clinicaltrials.gov NCT04621123 and NCT04589949. Registration: NCT04621123 and NCT04589949 on https://www.clinicaltrials.gov

Published
2022

39. Association between two mass-gathering outdoor events and incidence of SARS-CoV-2 infections during the fifth wave of COVID-19 in north-east Spain : A population-based control-matched analysis

Author

Suñer, Clara, Coma, Ermengol, Ouchi, Dan, Hermosilla, Eduardo, Baro, Barbara, Rodríguez-Arias, Miquel Àngel, Puig, Jordi, Clotet Sala, Bonaventura, Medina, Manuel, Mitjà, Oriol, and Universitat Autònoma de Barcelona

Subjects
Oncology, Health Policy, Internal Medicine
Abstract

Many countries have resumed mass-gathering events like music festivals, despite the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreading. In this study, we aimed to assess the effect of two mass-gathering outdoor events, held during a peak of SARS-CoV-2 transmission, on COVID-19 incidence.This was a retrospective, population-based control-matched analysis. The study population included attendees to two outdoor music festivals held in Catalonia (North-East Spain). The primary objective was to compare the incidence of COVID-19 within the 3-to-10 days following the event between attendees and a population-based control group.The analysis included 18,275 and 27,347 attendees to the first and second festivals, respectively, and their corresponding controls. The post-festival 7-day cumulative COVID-19 incidence among attendees and controls was 4.14% (95% CI 3.86-4.44) vs. 1.69% (1.51-1.88) for the first festival (RR 2.46; 2.16-2.80), and 2.42% (2.35-2.61) and 1.10% (0.99-1.2) for the second festival (RR 2.19; 1.92-2.51). COVID-19 incidence among immunized individuals was also two-fold higher in attendees than in controls. Previous COVID-19 infection, vaccination, and adequate mask-wearing were significantly associated with a lower risk of COVID-19 infection after the events.Despite the proven effectiveness of preventive measures such as Ag-RDT screening, mask-wearing and vaccination, caution should be taken when holding these events during a period of high community SARS-CoV-2 transmission.Crowdfunding campaign YoMeCorono (https://www.yomecorono.com/) and the Generalitat de Catalunya.

Published
2022

40. Mpox in people with advanced HIV infection: a global case series.

Author

Mitjà, Oriol, Alemany, Andrea, Marks, Michael, Lezama Mora, Jezer I, Rodríguez-Aldama, Juan Carlos, Torres Silva, Mayara Secco, Corral Herrera, Ever Arturo, Crabtree-Ramirez, Brenda, Blanco, José Luis, Girometti, Nicolo, Mazzotta, Valentina, Hazra, Aniruddha, Silva, Macarena, Montenegro-Idrogo, Juan José, Gebo, Kelly, Ghosn, Jade, Peña Vázquez, María Fernanda, Matos Prado, Eduardo, Unigwe, Uche, and Villar-García, Judit

Subjects
*IMMUNE reconstitution inflammatory syndrome, *HIV infections, *MONKEYPOX, *HIV-positive persons, *CD4 lymphocyte count, *VIRAL load
Abstract

People living with HIV have accounted for 38–50% of those affected in the 2022 multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell counts and similar outcomes to those without HIV. Emerging data suggest worse clinical outcomes and higher mortality in people with more advanced HIV. We describe the clinical characteristics and outcomes of mpox in a cohort of people with HIV and low CD4 cell counts (CD4 <350 cells per mm3). A network of clinicians from 19 countries provided data of confirmed mpox cases between May 11, 2022, and Jan 18, 2023, in people with HIV infection. Contributing centres completed deidentified structured case report sheets to include variables of interest relevant to people living with HIV and to capture more severe outcomes. We restricted this series to include only adults older than 18 years living with HIV and with a CD4 cell count of less than 350 cells per mm3 or, in settings where a CD4 count was not always routinely available, an HIV infection clinically classified as US Centers for Disease Control and Prevention stage C. We describe their clinical presentation, complications, and causes of death. Analyses were descriptive. We included data of 382 cases: 367 cisgender men, four cisgender women, and ten transgender women. The median age of individuals included was 35 (IQR 30–43) years. At mpox diagnosis, 349 (91%) individuals were known to be living with HIV; 228 (65%) of 349 adherent to antiretroviral therapy (ART); 32 (8%) of 382 had a concurrent opportunistic illness. The median CD4 cell count was 211 (IQR 117–291) cells per mm3, with 85 (22%) individuals with CD4 cell counts of less than 100 cells per mm3 and 94 (25%) with 100–200 cells per mm3. Overall, 193 (51%) of 382 had undetectable viral load. Severe complications were more common in people with a CD4 cell count of less than 100 cells per mm3 than in those with more than 300 cells per mm3, including necrotising skin lesions (54% vs 7%), lung involvement (29% vs 0%) occasionally with nodules, and secondary infections and sepsis (44% vs 9%). Overall, 107 (28%) of 382 were hospitalised, of whom 27 (25%) died. All deaths occurred in people with CD4 counts of less than 200 cells per mm3. Among people with CD4 counts of less than 200 cells per mm3, more deaths occurred in those with high HIV viral load. An immune reconstitution inflammatory syndrome to mpox was suspected in 21 (25%) of 85 people initiated or re-initiated on ART, of whom 12 (57%) of 21 died. 62 (16%) of 382 received tecovirimat and seven (2%) received cidofovir or brincidofovir. Three individuals had laboratory confirmation of tecovirimat resistance. A severe necrotising form of mpox in the context of advanced immunosuppression appears to behave like an AIDS-defining condition, with a high prevalence of fulminant dermatological and systemic manifestations and death. None. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials.

Author

Mitjà, Oriol, Reis, Gilmar, Boulware, David R., Spivak, Adam M., Sarwar, Ammar, Johnston, Christine, Webb, Brandon, Hill, Michael D., Smith, Davey, Kremsner, Peter, Curran, Marla, Carter, David, Alexander, Jim, Corbacho, Marc, Lee, Todd C., Hullsiek, Katherine Huppler, McDonald, Emily G., Hess, Rachel, Hughes, Michael, and Baeten, Jared M.

Subjects
*CORONAVIRUS disease treatment, *COVID-19, *HYDROXYCHLOROQUINE, *POLYMERASE chain reaction, *SEQUENTIAL analysis, *RANDOMIZED controlled trials, *ODDS ratio
Abstract

Hydroxychloroquine (HCQ) was initially promoted as an oral therapy for early treatment of coronavirus disease 2019 (COVID‐19). Conventional meta‐analyses cannot fully address the heterogeneity of different designs and outcomes of randomized controlled trials (RCTs) assessing the efficacy of HCQ in outpatients with mild COVID‐19. We conducted a pooled analysis of individual participant data from RCTs that evaluated the effect of HCQ on hospitalization and viral load reduction in outpatients with confirmed COVID‐19. We evaluated the overall treatment group effect by log‐likelihood ratio test (−2LL) from a generalized linear mixed model to accommodate correlated longitudinal binary data. The analysis included data from 11 RCTs. The outcome of virological effect, assessed in 1560 participants (N = 795 HCQ, N = 765 control), did not differ significantly between the two treatment groups (−2LL = 7.66; p = 0.18) when adjusting for cohort, duration of symptoms, and comorbidities. The decline in polymerase chain reaction positive tests from day 1 to 7 was 42.0 and 41.6 percentage points in the HCQ and control groups, respectively. Among the 2037 participants evaluable for hospitalization (N = 1058 HCQ, N = 979 control), we found no significant differences in hospitalization rate between participants receiving HCQ and controls (odds ratio 0.995; 95% confidence interval 0.614–1.610; −2LL = 0.0; p = 0.98) when adjusting for cohort, duration of symptoms, and comorbidities. This individual participant data meta‐analysis of 11 HCQ trials that evaluated severe acute respiratory syndrome‐coronavirus 2 viral clearance and COVID‐19 hospitalization did not show a clinical benefit of HCQ. Our meta‐analysis provides evidence to support the interruption in the use of HCQ in mild COVID‐19 outpatients to reduce progression to severe disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Rapid Serologic Test for Diagnosis of Yaws in Patients with Suspicious Skin Ulcers.

Author

Suñer, Clara, John, Lucy N., Houinei, Wendy, Ubals, Maria, Ouchi, Dan, Alemany, Andrea, Galván-Casas, Cristina, Marks, Michael, Mitjà, Oriol, Vall-Mayans, Martí, and Beiras, Camila G.

Subjects
SKIN ulcers, SYPHILIS, TREPONEMA pallidum, DIAGNOSTIC use of polymerase chain reaction, MEDICAL screening, ULCERS
Abstract

The Chembio DPP (Dual Path Platform) Syphilis Screen & Confirm kit (https://chembio.com) is a rapid serologic test that can be used to diagnose yaws. We evaluated its capacity to detect patients with ulcers that tested PCR positive for Treponema pallidum subsp. pertenue. DPP detected 84% of ulcers that were positive by PCR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Two Streptococcus pyogenes emm types and several anaerobic bacterial species are associated with idiopathic cutaneous ulcers in children after community-based mass treatment with azithromycin.

Author

Griesenauer, Brad, Ying, Xue, Fortney, Katherine R., Gao, Xiang, González-Beiras, Camila, Nelson, David E., Ren, Jie, Mitjà, Oriol, Dong, Qunfeng, and Spinola, Stanley M.

Subjects
TREPONEMA pallidum, STREPTOCOCCUS pyogenes, DISEASE eradication, AZITHROMYCIN, ULCERS, ANAEROBIC bacteria, NEGLECTED diseases
Abstract

Background: In yaws-endemic areas, two-thirds of exudative cutaneous ulcers (CU) are associated with Treponema pallidum subsp. pertenue (TP) and Haemophilus ducreyi (HD); one-third are classified as idiopathic ulcers (IU). A yaws eradication campaign on Lihir Island in Papua New Guinea utilizing mass drug administration (MDA) of azithromycin initially reduced but failed to eradicate yaws; IU rates remained constant throughout the study. Using 16S rRNA gene sequencing, we previously determined that Streptococcus pyogenes was associated with some cases of IU. Here, we applied shotgun metagenomics to the same samples we analyzed previously by 16S rRNA sequencing to verify this result, identify additional IU-associated microorganisms, and determine why S. pyogenes-associated IU might have persisted after MDA of azithromycin. Methodology/Principal findings: We sequenced DNA extracted from 244 CU specimens separated into four groups based upon microorganism-specific PCR results (HD+, TP+, TP+HD+, and TP-HD- or IU). S. pyogenes was enriched in IU (24.71% relative abundance [RA]) specimens compared to other ulcer sub-groups, confirming our prior results. We bioinformatically identified the emm (M protein gene) types found in the S. pyogenes IU specimens and found matches to emm156 and emm166. Only ~39% of IU specimens contained detectable S. pyogenes, suggesting that additional organisms could be associated with IU. In the sub-set of S. pyogenes-negative IU specimens, Criibacterium bergeronii, a member of the Peptostreptococcaceae, and Fusobacterium necrophorum (7.07% versus 0.00% RA and 2.18% versus 0.00% RA, respectively), were enriched compared to the S. pyogenes-positive sub-set. Although a broad range of viruses were detected in the CU specimens, none were specifically associated with IU. Conclusions/Significance: Our observations confirm the association of S. pyogenes with IU in yaws-endemic areas, and suggest that additional anaerobic bacteria, but not other microorganisms, may be associated with this syndrome. Our results should aid in the design of diagnostic tests and selective therapies for CU. Author summary: The World Health Organization classifies as a neglected tropical disease. It has been estimated that 100,000 children in 14 yaws-endemic countries develop cutaneous ulcers annually. The overall burden of infectious skin ulcers has not been determined and is likely to be much higher. Two-thirds of these ulcers are associated with Treponema pallidum subspecies pertenue and/or Haemophilus ducreyi, while the cause(s) of the remaining one-third are unknown. An ulcer eradication campaign on Lihir Island, Papua New Guinea, utilized mass drug administration of azithromycin and failed to fully eradicate ulcers in part due to the persistence of ulcers of unknown cause. By 16S rRNA gene sequencing, which only detects a subset of bacteria, we previously showed S. pyogenes was associated with skin ulcers of unknown origin. Here we applied direct DNA sequencing to identify other microorganisms present in these specimens. Confirming and extending our previous data, we found that Streptococcus pyogenes and several anaerobic bacteria were enriched in ulcers of unknown cause. We did not find enrichment of any viral or fungal microbes. Testing for S. pyogenes and selected anaerobes will help strengthen eradication efforts by improving diagnostic testing and treatment of this painful and debilitating syndrome. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Improved rapid diagnostic tests to detect syphilis and yaws: a systematic review and meta-analysis.

Author

Ying Zhang, Su MeiGoh, Mello, Maeve B., Baggaley, Rachel C., Teodora Wi, Johnson, Cheryl C., Asiedu, Kingsley B., Marks, Michael, Pham, Minh D., Fairley, Christopher K., Chow, Eric P. F., Mitjà, Oriol, Toskin, Igor, Ballard, Ronald C., Ong, Jason J., Zhang, Ying, Goh, Su Mei, and Wi, Teodora

Subjects
DIAGNOSIS of syphilis, RESEARCH funding, META-analysis, ROUTINE diagnostic tests, FERRANS & Powers Quality of Life Index, SYSTEMATIC reviews, YAWS, SENSITIVITY & specificity (Statistics)
Abstract

Background: Current rapid tests for syphilis and yaws can detect treponemal and non-treponemal antibodies. We aimed to critically appraise the literature for rapid diagnostic tests (RDTs) which can better distinguish an active infection of syphilis or yaws.Methods: We conducted a systematic review and meta-analysis, searching five databases between January 2010 and October 2021 (with an update in July 2022). A generalised linear mixed model was used to conduct a bivariate meta-analysis for the pooled sensitivity and specificity. Heterogeneity was assessed using the I2 statistic. We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) to assess the risk of bias and Grading of Recommendations, Assessment, Development and Evaluations (GRADE) to evaluate the certainty of evidence.Results: We included 17 studies for meta-analyses. For syphilis, the pooled sensitivity and specificity of the treponemal component were 0.93 (95% CI: 0.86 to 0.97) and 0.98 (95% CI: 0.96 to 0.99), respectively. For the non-treponemal component, the pooled sensitivity and specificity were 0.90 (95% CI: 0.82 to 0.95) and 0.97 (95% CI: 0.92 to 0.99), respectively. For yaws, the pooled sensitivity and specificity of the treponemal component were 0.86 (95% CI: 0.66 to 0.95) and 0.97 (95% CI: 0.94 to 0.99), respectively. For the non-treponemal component, the pooled sensitivity and specificity were 0.80 (95% CI: 0.55 to 0.93) and 0.96 (95% CI: 0.92 to 0.98), respectively.Conclusions: RDTs that can differentiate between active and previously treated infections could optimise management by providing same-day treatment and reducing unnecessary treatment.Prospero Registration Number: CRD42021279587. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Yaws

Author

Marks, Michael, Mitjà, Oriol, Solomon, Anthony W., Asiedu, Kingsley B., and Mabey, David C.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results